The FDA recently approved a drug therapy for cystic fibrosis (CF) that is being viewed as a “game-changer” for the roughly nine in 10 patients with the rare, progressive disease who might benefit from it — since previous breakthroughs in therapies to treat the illness and improve quality of life still left many patients without approved treatment options. Where does this leave payers facing rising specialty drug costs across the board? A health plan pharmacy executive, a physician with expertise on the illness and its treatment, and the product’s manufacturer predict that most payers likely will cover this latest cystic fibrosis treatment option despite an annual price tag topping $300,000.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.